Table 1.

CenterWatch list of new indications related to nephrology, 2002–2012

DrugYear ApprovedManufacturerIndication
Mesnex2002Bristol-Myers SquibbOral tablet to inhibit the hemorrhagic cystitis induced by Ifex
Eligard2002Atrix LaboratoriesFor the palliative treatment of advanced prostate cancer
UroXatral2002Sanori-aventisFor the treatment of the signs and symptoms of benign prostatic hyperplasia
Oxytrol2003Watson PharmaceuticalsFor the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Fabrazyme2003GenzymeFor the treatment of Fabry disease in adult patients
Vesicare2004Yamanouchi, GlaxoSmithKlineFor the treatment of overactive bladder with symptoms of urge urinary incontinence
Sensipar2004AmgenFor the treatment of secondary hyperparathyroidism and hypercalcemia in parathyroid carcinoma patients
Sanctura2004Indevus PharmaceuticalsFor the treatment of overactive bladder with symptoms of urge urinary incontinence
Fosrenol2004Shire PharmaceuticalsFor the treatment of hyperphosphatemia related to kidney dysfunction
Vaprisol2005AstellasFor the treatment of euvolemic hyponatremia
Torisel2007WyethFor the treatment of renal cell carcinoma
Renvela2007GenzymeFor the control of serum phosphorus in patients with CKD on dialysis
Mircera2007RocheFor the treatment of anemia associated with chronic renal failure
Doribax2007Johnson & JohnsonFor the treatment of intra-abdominal infections and urinary tract infections
Toviaz2008PfizerFor the treatment of overactive bladder
Degarelix2008Ferring PharmaceuticalsFor the treatment of prostate cancer
Votrient2009GlaxoSmithKlineFor the treatment of renal cell carcinoma
Gelnique2009Watson PharmaceuticalsFor the treatment of overactive bladder
Feraheme2009AMAGFor the treatment of iron deficiency anemia associated with CKD
Avastin2009GenentechFor the treatment of renal cell carcinoma
Afinitor2009NovartisFor the treatment of renal cell carcinoma
Zortress2010NovartisFor the prevention of organ rejection after kidney transplant
Xifaxan2010SalixFor the treatment of hepatic encephalopathy
Provenge2010DendreonFor the treatment of hormone refractory prostate cancer
Jevtana2010Sanori-aventisFor the treatment of prostate cancer
Jalyn2010GlaxoSmithKlineFor the treatment of benign prostatic hyperplasia
Carbaglu2010RecordatiFor the treatment of hyperammonemia
Soliris2011AlexionFor the treatment of atypical hemolytic uremic syndrome
Nulojix2011Bristol-Myers SquibbFor the prevention of organ rejection after kidney transplant
Anturol2011Antares PharmaFor the treatment of overactive bladder
Voraxaze2012BTG InternationalFor the treatment of toxic plasma methotrexate concentrations in patients with impaired renal function
Stivarga2012Bayer HealthCare PharmaceuticalsFor the treatment of previously treated patients with metastatic colorectal cancer
Stendra2012VivusFor the treatment of erectile dysfunction
Omontys2012AffymaxFor the treatment of anemia caused by CKD
Myrbetriq2012Astellas Pharma US, Inc.For the treatment of overactive bladder
Inlyta2012PfizerFor the treatment of advanced renal cell carcinoma
Afinitor2012NovartisFor the treatment of renal angiomyolipoma associated with tuberous sclerosis complex